Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index; 43 of the 65 sources its claims cite were checked for support.

Intravitreal AAV vector delivery induces integrin-dependent ocular inflammation, complement activation, and antiviral and DNA damage responses

Open access

Abstract

Background: Intravitreal delivery of adeno-associated virus (AAV) vectors offers a promising, minimally invasive strategy for retinal gene therapy, but remains limited by dose-dependent intraocular inflammation. Corticosteroid therapy, the current standard for managing gene therapy-associated uveitis (GTAU), can be ineffective or contraindicated, highlighting the need for alternative immunomodulatory approaches and deeper understanding of AAV-induced inflammation. Methods: Using porcine and mice models, we characterized immune responses triggered by AAV2.7m8 vector. Results: Consistent with previous data for this serotype, AAV-mediated transgene expression localized predominantly to retinal ganglion cells, although photoreceptor, bipolar, amacrine, horizontal, and glia cells were also transduced. Despite prophylactic methylprednisolone, AAV-treated animals developed GTAU, accompanied by increased MCP-1, IP-10, MIP-1α and IL-6 levels in ocular humors, along with microglial activation and peripheral leukocyte infiltration. Transcriptomic analysis revealed upregulation of antiviral interferon responses across all retinal cell populations, together with complement and DNA damage pathways. Accordingly, functional assays confirmed complement C3a accumulation in ocular humors and presence of γH2AX + DNA damage foci in transduced retinas. Finally, a mechanistic study of intravitreal AAV delivery in mice using integrin-blocking antibodies revealed a role for peripheral leukocytes in mediating ocular inflammation in this species. Conclusion: Our work identified new markers of ocular inflammation and potential targets to modulate GTAU.

Overview

CoChat Summary

TL;DR

Intravitreal AAV2.7m8 delivery in pigs induced gene therapy-associated uveitis despite prophylactic methylprednisolone, with complement activation, antiviral interferon and DNA damage responses, microglial activation, and peripheral leukocyte infiltration. In mice, dual integrin blockade with anti-LFA-1/VLA-4 antibodies prevented leukocyte infiltration, reduced inflammatory chemokines, and increased transgene expression.

Key findings

  • In pigs, bilateral IVT AAV2.7m8/CAG-GFP at 5×10¹¹ vg/eye (n = 7) versus vehicle (n = 5) transduced all retinal layers, with strongest GFP signal in the GCL; 70.65% ± 7.78 of Brn3a+ RGCs were GFP+, and snRNAseq showed GFP+ nuclei most abundant among bipolar (38.3%), rod (22.3%), and amacrine cells (16.1%).
  • Despite weekly systemic methylprednisolone, AAV-treated pigs developed uveitis, complement C3a elevation in aqueous humor as early as week 1 and vitreous humor at week 4, and increased MCP-1/IP-10 in AH by week 1 and VH by week 2, with later IL-6 and MIP-1α increases.
  • snRNAseq showed upregulated interferon, IL-6, TNFα, apoptosis, and complement pathways across retinal populations, plus p53/DNA damage response in Müller and bipolar cells at week 2 extending to astrocytes, horizontal cells, RGCs, and microglia by week 4; γH2AX+ foci were confirmed across retinal layers by week 4.
  • In mice, IVT AAV2.7m8/CAG-GFP at 1×10⁹ vg/eye caused CD45+ monocyte and dendritic cell accumulation by 2 weeks and lymphocyte infiltration by 4 weeks; anti-LFA-1/VLA-4 blockade prevented infiltration of affected immune populations, reduced vitreous IP-10 and MCP-1, and was associated with higher GFP mean fluorescence intensity.

Methods

  • Pigs: female Yucatan minipigs, 3–5 months old, pre-screened for anti-AAV2.7m8 neutralizing antibodies, received bilateral IVT AAV2.7m8/CAG-GFP or AAV2.7m8/CAG-hFIX at 5×10¹¹ vg/eye or vehicle, with intramuscular methylprednisolone 5 mg/kg two days before and weekly thereafter; readouts included ocular exams, OCT/BAF, fundus imaging, AH/VH cytokine and C3a assays, anti-AAV IgG ELISA, flow cytometry, immunofluorescence, RNAscope, and snRNAseq.
  • Mice: female C57BL/6J mice, 8–12 weeks old, received bilateral IVT vehicle or AAV2.7m8/CAG-GFP at 1×10⁹ vg/eye; an additional group received intraperitoneal anti-VLA-4/LFA-1 antibodies on day 0 and every 3 days until day 28; readouts included fundus imaging, flow cytometry of ocular homogenates, and vitreous cytokine analysis.
  • Analysis: snRNAseq was processed with Cellranger and Seurat, integrated with SCTransform, clustered with Louvain, and analyzed by differential expression and GSEA using Hallmark gene sets; statistics used GraphPad Prism 10 with one-way ANOVA/Tukey, Mann-Whitney, or Welch’s t-test as indicated.

Limitations

  • The paper states that species-specific features of the porcine immune system warrant further validation, that the positive effect of inhibiting immune cell infiltration in mice may be limited in larger species, and that no single dominant trigger of AAV immunogenicity was identified.
  • The paper states that further studies are needed to confirm whether DNA damage response leads to apoptosis and cell death, and that GFP transgene expression quantification from mouse color fundus images is subject to technical limitations and multiple sources of variation.
  • The paper notes that absence of significant T cell infiltration in pig retinas could be due to steroid treatment in pigs but not mice, or to interspecies differences; evident from the text, group sizes were small, some pigs were sacrificed prematurely due to inflammation, and one AAV-injected animal received topical corticosteroids.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3389/fimmu.2026.1799327

Cites

63 of 63 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Preliminary assessment of intravitreal gene transfer in the pig shows early inflammation post-AAV injection. (A) Animals received intravitreal (IVT) injections of AAV2.7m8/CAG-hFIX (n = 3) at 5x1011 vg/eye or vehicle (n = 2) on day 0. Prophylactic methylprednisolone was administered intramuscularly (I.M.) from day -2 and weekly thereafter. Animals were sacrificed on day 28. (B) Total uveitis scores in AAV2.7m8/CAG-hFIX-injected eyes (n = 6) overtime, compared to vehicle control eyes (n = 4) at terminal timepoint. Bars represent mean uveitis score. Symbols show individual scores in each eye. Different symbols represent pairs of eyes belonging to the same animal. Open circles identify eyes from the animal that received corticosteroids on Day 8. Statistical significance was determined by two-way ANOVA with Bonferroni correction. *P = 0.0367. Analysis of (C) complement C3a, (D) cytokines and chemokines MCP-1, IP-10, IL-6 and MIP-1α and (E) anti-AAV2.7m8 IgG in aqueous (AH) and vitreous (VH) humors at terminal timepoint. For C-E, data are represented as mean between 2 vehicle- and 4 AAV-injected eyes. (F) Flow cytometry analysis of the frequencies of CD45+ cells, T cells, antigen presenting cells (APC), monocytes and dendritic cells (DCs) in total ocular homogenates. Data are shown as mean ± SD between 4 vehicle- and 4 AAV-injected eyes. Statistical significance was determined by Mann-Whitney t-test. In all cases, *p = 0.0286.
Figure 1 Preliminary assessment of intravitreal gene transfer in the pig shows early inflammation post-AAV injection. (A) Animals received intravitreal (IVT) injections of AAV2.7m8/CAG-hFIX (n = 3) at 5x1011 vg/eye or vehicle (n = 2) on day 0. Prophylactic methylprednisolone was administered intramuscularly (I.M.) from day -2 and weekly thereafter. Animals were sacrificed on day 28. (B) Total uveitis scores in AAV2.7m8/CAG-hFIX-injected eyes (n = 6) overtime, compared to vehicle control eyes (n = 4) at terminal timepoint. Bars represent mean uveitis score. Symbols show individual scores in each eye. Different symbols represent pairs of eyes belonging to the same animal. Open circles identify eyes from the animal that received corticosteroids on Day 8. Statistical significance was determined by two-way ANOVA with Bonferroni correction. *P = 0.0367. Analysis of (C) complement C3a, (D) cytokines and chemokines MCP-1, IP-10, IL-6 and MIP-1α and (E) anti-AAV2.7m8 IgG in aqueous (AH) and vitreous (VH) humors at terminal timepoint. For C-E, data are represented as mean between 2 vehicle- and 4 AAV-injected eyes. (F) Flow cytometry analysis of the frequencies of CD45+ cells, T cells, antigen presenting cells (APC), monocytes and dendritic cells (DCs) in total ocular homogenates. Data are shown as mean ± SD between 4 vehicle- and 4 AAV-injected eyes. Statistical significance was determined by Mann-Whitney t-test. In all cases, *p = 0.0286.CC BY · PubMed Central
Figure 2 Intravitreally dosed AAV2.7m8 distributed across the pig retina and induced the highest transgene expression in GCL. (A) Animals received bilateral intravitreal (IVT) injections of AAV2.7m8/CAG-GFP (n = 7) at 5x1011 vg/eye or vehicle (n = 5) on day 0. Prophylactic methylprednisolone was administered intramuscularly (I.M.) from day -2 and weekly thereafter. Animals were sacrificed on days 15 (week 2), 24 (week 4 cohort 1) or 28 (week 4 cohort 2) as indicated. (B) Representative fundus images of GFP fluorescence (top) and confocal scanning laser ophthalmoscopy with blue autofluorescence (BAF) (bottom) in vehicle- and AAV-injected eyes at different timepoints post-injection. (C) UMAP of GFP mRNA distribution. (D) Stacked barplot showing the cell type frequencies among GFP+ nuclei. (E) Quantification of the percentage of GFP mRNA+ cells and mean GFP reads per cell population in AAV-injected retinas on week 4 presented as mean ± SD per cell population. (F) Representative IF images of GFP protein expression (yellow) and AAV vector genomes by RNAscope using probes against the CAG promoter (white), in retina sections from two different vehicle- and AAV-injected animals, 4 weeks post-injection. Sale bar 100μM.
Figure 2 Intravitreally dosed AAV2.7m8 distributed across the pig retina and induced the highest transgene expression in GCL. (A) Animals received bilateral intravitreal (IVT) injections of AAV2.7m8/CAG-GFP (n = 7) at 5x1011 vg/eye or vehicle (n = 5) on day 0. Prophylactic methylprednisolone was administered intramuscularly (I.M.) from day -2 and weekly thereafter. Animals were sacrificed on days 15 (week 2), 24 (week 4 cohort 1) or 28 (week 4 cohort 2) as indicated. (B) Representative fundus images of GFP fluorescence (top) and confocal scanning laser ophthalmoscopy with blue autofluorescence (BAF) (bottom) in vehicle- and AAV-injected eyes at different timepoints post-injection. (C) UMAP of GFP mRNA distribution. (D) Stacked barplot showing the cell type frequencies among GFP+ nuclei. (E) Quantification of the percentage of GFP mRNA+ cells and mean GFP reads per cell population in AAV-injected retinas on week 4 presented as mean ± SD per cell population. (F) Representative IF images of GFP protein expression (yellow) and AAV vector genomes by RNAscope using probes against the CAG promoter (white), in retina sections from two different vehicle- and AAV-injected animals, 4 weeks post-injection. Sale bar 100μM.CC BY · PubMed Central
Figure 3 Intravitreally dosed AAV2.7m8 activates DNA damage and robust antiviral responses in pig retinas. (A) Heatmaps showing enriched GSEA terms in retinas from AAV-injected animals collected 2- and 4-weeks post-injection, against the Hallmark gene set (Molecular Signatures Database). Each column represents the average between 2 eyes. GSEA was performed on logFC fold changes in gene expression compared to vehicle controls (NES, normalized enrichment score; *, adjusted p <0.05). (B) Heatmaps showing top upregulated and downregulated genes in retinas from AAV-injected animals at the indicated timepoints and their contribution to IFN signaling according to the Hallmark gene set. ISG, interferon stimulated gene. (C) Representative IF images of p-ɣH2AX+ foci and GFP expression in retina sections from different vehicle and AAV-injected animals, 4 weeks post-injection. Scale bar 200μM. (D) Quantification of nuclear p-ɣH2AX mean fluorescence intensity (MFI) per cell. Dots represent MFI values per individual DAPI+ nucleus, pooled from 3 vehicle- and 5 AAV-injected animals, 2 ROIs per animal. Statistical significance was determined by Welch’s t-test. (E) Representative scatter plot of GFP and p-ɣH2AX colocalization analysis from one representative ROI, generated with MACS IQ View Software. **** symbol corresponds to the P < 0.0001.
Figure 3 Intravitreally dosed AAV2.7m8 activates DNA damage and robust antiviral responses in pig retinas. (A) Heatmaps showing enriched GSEA terms in retinas from AAV-injected animals collected 2- and 4-weeks post-injection, against the Hallmark gene set (Molecular Signatures Database). Each column represents the average between 2 eyes. GSEA was performed on logFC fold changes in gene expression compared to vehicle controls (NES, normalized enrichment score; *, adjusted p <0.05). (B) Heatmaps showing top upregulated and downregulated genes in retinas from AAV-injected animals at the indicated timepoints and their contribution to IFN signaling according to the Hallmark gene set. ISG, interferon stimulated gene. (C) Representative IF images of p-ɣH2AX+ foci and GFP expression in retina sections from different vehicle and AAV-injected animals, 4 weeks post-injection. Scale bar 200μM. (D) Quantification of nuclear p-ɣH2AX mean fluorescence intensity (MFI) per cell. Dots represent MFI values per individual DAPI+ nucleus, pooled from 3 vehicle- and 5 AAV-injected animals, 2 ROIs per animal. Statistical significance was determined by Welch’s t-test. (E) Representative scatter plot of GFP and p-ɣH2AX colocalization analysis from one representative ROI, generated with MACS IQ View Software. **** symbol corresponds to the P < 0.0001.CC BY · PubMed Central
Figure 4 Kinetic assessment shows early inflammation accompanied by complement activation, chemokine accumulation and anti-AAV IgG development in ocular humors. (A) Total uveitis scores in AAV/GFP-injected animals over time. Data correspond to the mean between both eyes from the same animal from 7 AAV-injected animals. Statistical significance against vehicle week 4 was determined by one-way ANOVA with Tukey correction. **** P < 0.0001 vs. baseline (week 0). (B) Representative OCT showing horizontal scans from vehicle- and AAV-injected retinas at terminal timepoint week 4. (C) Quantification of total retinal thickness (TRT) derived from horizontal retinal scans over time. Data correspond to individual eyes from 4 vehicle controls (week 4) and 7 AAV-injected animals over time, and are represented as mean ± SD. Statistical significance was determined by one-way ANOVA with Tukey correction. *P = 0.0383. Analysis of (D) complement factor C3a, (E) MCP-1, (F) IP-10, (G) IL-6 and (H) MIP-1α and (I) anti-AAV2.7m8 IgG in AH and VH at the indicated timepoints. For C-I, eyes with a uveitis score of 0 belong to cohort 2 and are highlighted in light purple. For C-H, data are represented as mean ± SD between individual eyes from 5 vehicle- and 7 AAV/GFP-injected animals. For detailed N refer to supplementary table 5. For AH samples, statistical significance between all timepoints vs. vehicle was determined by one-way ANOVA with Tukey correction. For VH samples, statistical significance between week 4 group and vehicle was determined by Mann-Whitney t-test. *P < 0.05, **p < 0.01, p < 0.001, *** p < 0.0001 vs. vehicle.
Figure 4 Kinetic assessment shows early inflammation accompanied by complement activation, chemokine accumulation and anti-AAV IgG development in ocular humors. (A) Total uveitis scores in AAV/GFP-injected animals over time. Data correspond to the mean between both eyes from the same animal from 7 AAV-injected animals. Statistical significance against vehicle week 4 was determined by one-way ANOVA with Tukey correction. **** P < 0.0001 vs. baseline (week 0). (B) Representative OCT showing horizontal scans from vehicle- and AAV-injected retinas at terminal timepoint week 4. (C) Quantification of total retinal thickness (TRT) derived from horizontal retinal scans over time. Data correspond to individual eyes from 4 vehicle controls (week 4) and 7 AAV-injected animals over time, and are represented as mean ± SD. Statistical significance was determined by one-way ANOVA with Tukey correction. *P = 0.0383. Analysis of (D) complement factor C3a, (E) MCP-1, (F) IP-10, (G) IL-6 and (H) MIP-1α and (I) anti-AAV2.7m8 IgG in AH and VH at the indicated timepoints. For C-I, eyes with a uveitis score of 0 belong to cohort 2 and are highlighted in light purple. For C-H, data are represented as mean ± SD between individual eyes from 5 vehicle- and 7 AAV/GFP-injected animals. For detailed N refer to supplementary table 5. For AH samples, statistical significance between all timepoints vs. vehicle was determined by one-way ANOVA with Tukey correction. For VH samples, statistical significance between week 4 group and vehicle was determined by Mann-Whitney t-test. *P < 0.05, **p < 0.01, p < 0.001, *** p < 0.0001 vs. vehicle.CC BY · PubMed Central
Figure 5 AAV-mediated retinal transduction leads to microglia activation. (A) UMAP plots showing cell populations identified in retinas from vehicle- and AAV-injected animals generated with Seurat. Plots show clustered results from 2 eyes per condition. UMAP of gene expression distribution and quantification of the percentage of (B) MCP-1 and (C) IP-10 mRNA-positive cells per cluster in AAV-injected retinas. (D) Representative IF images of Iba1 and SLA-DR staining in retina sections. Scale bar 200μM. Quantification of (E) Iba1 and (F) SLA-DR cell stainings in retina sections from vehicle- and AAV-injected animals 4 weeks post-injection. For E and F, individual dots represent mean fluorescence intensity (MFI) values per DAPI+ cell, pooled from 3 vehicle- and 5 AAV-injected animals, 2 ROIs per animal. Statistical significance was determined by Welch’s t-test. **** P < 0.0001. (G) Quantification of the percentage of Iba1+SLA-DR+ double positive cells. Data are shown as mean ± SD between individual ROIs from 3 vehicle- and 5 AAV-injected animals, 2 ROIs per animal. Statistical significance was determined by Mann-Whitney t-test. ***P = 0.0002.
Figure 5 AAV-mediated retinal transduction leads to microglia activation. (A) UMAP plots showing cell populations identified in retinas from vehicle- and AAV-injected animals generated with Seurat. Plots show clustered results from 2 eyes per condition. UMAP of gene expression distribution and quantification of the percentage of (B) MCP-1 and (C) IP-10 mRNA-positive cells per cluster in AAV-injected retinas. (D) Representative IF images of Iba1 and SLA-DR staining in retina sections. Scale bar 200μM. Quantification of (E) Iba1 and (F) SLA-DR cell stainings in retina sections from vehicle- and AAV-injected animals 4 weeks post-injection. For E and F, individual dots represent mean fluorescence intensity (MFI) values per DAPI+ cell, pooled from 3 vehicle- and 5 AAV-injected animals, 2 ROIs per animal. Statistical significance was determined by Welch’s t-test. **** P < 0.0001. (G) Quantification of the percentage of Iba1+SLA-DR+ double positive cells. Data are shown as mean ± SD between individual ROIs from 3 vehicle- and 5 AAV-injected animals, 2 ROIs per animal. Statistical significance was determined by Mann-Whitney t-test. ***P = 0.0002.CC BY · PubMed Central
Figure 6 LFA-1/VLA-4 neutralization prevents IOI after intravitreal AAV vector dosing in mice. (A) Study design. Female C57Bl/6J mice received intravitreal (IVT) bilateral injections of AAV2.7m8/CAG-GFP (1x109 vg/eye) or vehicle control on day 0 and sacrificed at different timepoints as indicated in the scheme. One cohort of AAV-injected mice received concomitant intraperitoneal (I.P.) injections of anti-LFA-1/VLA-4 antibodies on day 0, and every 3 days until termination (week 4). (B) FACS analysis of ocular infiltrates in ocular homogenates. Both eyes from from the same animal were pooled for analysis. Data are shown as mean ± SD between n = 5 week 1, n = 5 week 2, n = 9 week 4 and n = 10 αLFA-1/VLA-4-treated week 4 animals, and represented as fold change between AAV-injected animals relative to vehicle controls. The dashed line represents values in vehicle controls, set at 1. Statistical significance for each timepoint was determined respect to its own vehicle control by one-way ANOVA with Fisher’s LSD test (n = 5 for vehicles week 1 and 2, n = 10 vehicle week 4). *P < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 vs. vehicle; ### p < 0.001, #### p < 0.0001 vs. AAV week 4. (C) Quantification of cytokines and chemokines in vitreous humors. Each dot corresponds to a pool between 4 eyes from 2 animals from the same treatment group. Data are shown as ± SD between pools (n = 5 for vehicle and αLFA-1/VLA-4-treated animals, n = 4 for AAV-treated only). Statistical significance was determined by two-way ANOVA with Tukey’s correction. ****P < 0.0001. (D) Representative fundus images of GFP expression over time. (E) Quantification of GFP mean fluorescence intensity (MFI) in mice injected with AAV only (n = 8) or with AAV + anti-LFA-1/anti-VLA-4 (n = 9). Data are shown as mean ± SD between individual eyes. Statistical significance was determined by two-way ANOVA with Bonferroni correction. *** P = 0.0005.
Figure 6 LFA-1/VLA-4 neutralization prevents IOI after intravitreal AAV vector dosing in mice. (A) Study design. Female C57Bl/6J mice received intravitreal (IVT) bilateral injections of AAV2.7m8/CAG-GFP (1x109 vg/eye) or vehicle control on day 0 and sacrificed at different timepoints as indicated in the scheme. One cohort of AAV-injected mice received concomitant intraperitoneal (I.P.) injections of anti-LFA-1/VLA-4 antibodies on day 0, and every 3 days until termination (week 4). (B) FACS analysis of ocular infiltrates in ocular homogenates. Both eyes from from the same animal were pooled for analysis. Data are shown as mean ± SD between n = 5 week 1, n = 5 week 2, n = 9 week 4 and n = 10 αLFA-1/VLA-4-treated week 4 animals, and represented as fold change between AAV-injected animals relative to vehicle controls. The dashed line represents values in vehicle controls, set at 1. Statistical significance for each timepoint was determined respect to its own vehicle control by one-way ANOVA with Fisher’s LSD test (n = 5 for vehicles week 1 and 2, n = 10 vehicle week 4). *P < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 vs. vehicle; ### p < 0.001, #### p < 0.0001 vs. AAV week 4. (C) Quantification of cytokines and chemokines in vitreous humors. Each dot corresponds to a pool between 4 eyes from 2 animals from the same treatment group. Data are shown as ± SD between pools (n = 5 for vehicle and αLFA-1/VLA-4-treated animals, n = 4 for AAV-treated only). Statistical significance was determined by two-way ANOVA with Tukey’s correction. ****P < 0.0001. (D) Representative fundus images of GFP expression over time. (E) Quantification of GFP mean fluorescence intensity (MFI) in mice injected with AAV only (n = 8) or with AAV + anti-LFA-1/anti-VLA-4 (n = 9). Data are shown as mean ± SD between individual eyes. Statistical significance was determined by two-way ANOVA with Bonferroni correction. *** P = 0.0005.CC BY · PubMed Central

Verification

Claims the paper makes

21 Valid · 1 Not valid · 6 Not checked · 85 Own results and interpretations

60 more claims · 3 with their cited sources checked

Create a free account to see all 113 claims and to verify the 1 reference still open.

See all claims — free account
  • It may state two separate claims as one. 32
  • Probably not a substantial claim. 14
  • The quote only partly states this claim. 4

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

3 of 3

Citations

Cites

Show all 60 references

Research works printed but not linked: 3

  1. Buckley, 2024, Meta-analysis of gene therapy associated uveitis (GTAU), Invest Ophthalmol Visual Sci, 65, 5312
  2. Chandler, 2019, Enhancement of adeno-associated virus-mediated gene therapy using hydroxychloroquine in murine and human tissues, Mol Ther Methods Clin Dev, 14, 77, 10.1016/j.omtm.2023.01.001 · DOI · Paper page
  3. Kropf, 2024, C3 Complement Inhibitor Limits Transaminitis and Immune Response Following Liver Targeted Adeno-Associated Virus (AAV) Gene Transfer (GT) in Non-Human Primates (NHPs), Mol Ther, 32

Cited by

See all 2

Metadata

Authors
Costa-Verdera, H., Jamwal, D., Fabyanic, E., Hippen, A., Salvatore, M., Du, A., Majowicz, A., Markusic, D., Chatterton, J. E., Haurigot, V., & Kuranda, K.
Affiliations
  • Immunology, Spark Therapeutics
  • Spark Therapeutics (United States) (US)
Corresponding author
Chatterton, Jon E.
Venue
Frontiers in Immunology
Published
2026-04-22
Volume
17
Pages
1799327-1799327
ISSN
1664-3224 (ISSN-L)
OpenAlex
W7155194333
Cited by
2
References
60
Citations by year
2026: 2
FWCI
7.85
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Immunology (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
  • Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
Keywords
adeno-associated virus vectors, intravitreal gene delivery, ocular inflammation, integrin signaling, complement activation, C3a, DNA damage response, retinal ganglion cells, microglial activation, retinal gene therapy, immunomodulation
MeSH terms
Gene Therapy Agents, Dependovirus, Animals, Complement Activation, Disease Models, Animal, DNA Damage, Female, Genetic Vectors, Swine, Uveitis, Genetic Therapy, Integrins, Mice, Intravitreal Injections

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-09-29, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-09-29 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Intravitreal AAV vector delivery induces integrin-dependent ocular inflammation, complement activation, and antiviral and DNA damage responses. https://app.cochat.ai/papers/10.3389/fimmu.2026.1799327
The paper
Costa-Verdera, H., Jamwal, D., Fabyanic, E., Hippen, A., Salvatore, M., Du, A., Majowicz, A., Markusic, D., Chatterton, J. E., Haurigot, V., & Kuranda, K. (2026). Intravitreal AAV vector delivery induces integrin-dependent ocular inflammation, complement activation, and antiviral and DNA damage responses. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2026.1799327

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.